Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAd-p53 with TACE in Advanced Hepatocellular Carcinoma
NCT02418988Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Jul 2014
- Primary completion
- May 2017
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAdp53 in hepatocellular carcinoma (HCC), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
rAdp53
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02418988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418988.